Ivosidenib
Författaruppgift saknas
Journal missing · review PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för ivosidenib. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
19 hitsIvosidenib induction therapy complicated by myopericarditis and cardiogenic shock: A case report and literature review.
Hernandez Burgos P, Patel J, Chen A.
J Oncol Pharm Pract · review; journal article; case reports · DOI 10.1177/1078155219865934Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.
Lowery MA, Burris HA, Janku F, Shroff RT, Cleary JM, Azad NS, Goyal L, Maher EA, Gore L, Hollebecque A, Beeram M, Trent JC, Jiang L, Fan B, Aguado-Fraile E, Choe S, Wu B, Gliser C, Agresta SV, Pandya SS, Zhu AX, Abou-Alfa GK.
Lancet Gastroenterol Hepatol · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1016/s2468-1253(19)30189-xClinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors.
Fan B, Mellinghoff IK, Wen PY, Lowery MA, Goyal L, Tap WD, Pandya SS, Manyak E, Jiang L, Liu G, Nimkar T, Gliser C, Prahl Judge M, Agresta S, Yang H, Dai D.
Invest New Drugs · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1007/s10637-019-00771-xEffect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects.
Dai D, Yang H, Nabhan S, Liu H, Hickman D, Liu G, Zacher J, Vutikullird A, Prakash C, Agresta S, Bowden C, Fan B.
Eur J Clin Pharmacol · clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1007/s00228-019-02673-6Quantitation of Ivosidenib, A Novel Mutant IDH1 Inhibitoron Mice DBS: Application to a Pharmacokinetic Study.
Dittakavi S, Jat RK, Mullangi R.
Drug Res (Stuttg) · journal article · DOI 10.1055/a-0857-6591Pharmacokinetics, absorption, metabolism, and excretion of [<sup>14</sup>C]ivosidenib (AG-120) in healthy male subjects.
Prakash C, Fan B, Altaf S, Agresta S, Liu H, Yang H.
Cancer Chemother Pharmacol · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1007/s00280-019-03793-7FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation.
Norsworthy KJ, Luo L, Hsu V, Gudi R, Dorff SE, Przepiorka D, Deisseroth A, Shen YL, Sheth CM, Charlab R, Williams GM, Goldberg KB, Farrell AT, Pazdur R.
Clin Cancer Res · journal article · DOI 10.1158/1078-0432.ccr-18-3749Correction to: Ivosidenib: First Global Approval.
Dhillon S.
Drugs · published erratum; correction; journal article · DOI 10.1007/s40265-018-1050-zIvosidenib in IDH1-Mutated Acute Myeloid Leukemia.
Yun S, Vincelette ND.
N Engl J Med · letter; comment · DOI 10.1056/nejmc1809507Ivosidenib: First Global Approval.
Dhillon S.
Drugs · research-article; review; journal article · DOI 10.1007/s40265-018-0978-3Ivosidenib in IDH1-Mutated Acute Myeloid Leukemia.
DiNardo CD.
N Engl J Med · letter; comment · DOI 10.1056/nejmc1809507Ivosidenib in IDH1-Mutated Acute Myeloid Leukemia.
Sahin I.
N Engl J Med · letter; comment · DOI 10.1056/nejmc1809507Ivosidenib Gets Go-Ahead for AML.
Författaruppgift saknas
Cancer Discov · news · DOI 10.1158/2159-8290.cd-nb2018-107Ivosidenib effective in IDH1-mutant AML.
Sidaway P.
Nat Rev Clin Oncol · comment; journal article · DOI 10.1038/s41571-018-0057-4Ivosidenib Deemed Safe, Effective in AML.
Författaruppgift saknas
Cancer Discov · comment; news · DOI 10.1158/2159-8290.cd-nb2018-082Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea DA, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM.
N Engl J Med · research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.1056/nejmoa1716984Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.
Popovici-Muller J, Lemieux RM, Artin E, Saunders JO, Salituro FG, Travins J, Cianchetta G, Cai Z, Zhou D, Cui D, Chen P, Straley K, Tobin E, Wang F, David MD, Penard-Lacronique V, Quivoron C, Saada V, de Botton S, Gross S, Dang L, Yang H, Utley L, Chen Y, Kim H, Jin S, Gu Z, Yao G, Luo Z, Lv X, Fang C, Yan L, Olaharski A, Silverman L, Biller S, Su SM, Yen K.
ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/acsmedchemlett.7b00421Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.
Birendra KC, DiNardo CD.
Clin Lymphoma Myeloma Leuk · research support, non-u.s. gov't; research-article; journal article; case reports; research support, n.i.h., extramural · DOI 10.1016/j.clml.2016.04.006